Creso Pharma has a lot on its microwave-warmed plate at the moment, having lost director Adam Blumenthal last month. He had previously demoted himself from chairman following raids by the Australian Federal Police at the listed pot stock’s offices and his brokerage EverBlu Capital.

But these matters, and the Australian Securities and Investments Commission’s continuing investigation into suspected rigged trading in Creso shares, appear to have been far from the mind of Dr James Ellingford.